Novel indicators of transplant outcomes for PhALL: “current molecular-relapse-free survival”

Generally, patients with Philadelphia chromosome −positive acute lymphoblastic leukemia (PhALL) are considered to have inferior survival outcomes, and allogeneic hematopoietic cell transplantation (allo-HCT) has been offered to eligible patients.1-3 The introduction of tyrosine kinase inhibitor (TKI) has contributed to the improvement of clinica l outcomes for PhALL. Historically, the combination of chemotherapies and TKI has induced durable molecular remission, and a growing number of PhALL patients have become eligible to receive allo-HCT during their first remission.

Source: Biology of Blood and Marrow Transplantation - June 22, 2021 Category: Hematology Authors: Hideki Nakasone, Shinichi Kako, Takayoshi Tachibana, Masatsugu Tanaka, Makoto Onizuka, Satoshi Takahashi, Akira Yokota, Shin-ichiro Fujiwara, Toru Sakura, Emiko Sakaida, Shin Fujisawa, Rie Yamazaki, Moritaka Gotoh, Maki Hagihara, Nobuyuki Aotsuka, Nobuhir Source Type: research